Please assess the completion status of the following clinical trial:

Trial Title: Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with the clinical diagnosis of generalized epilepsy with generalised onset motor seizure (ILAE 2017) with a history of an episode of seizure within 72 hours of presentation.~* Patients aged 18-60 years, of either sex.~* Treatment-naive patients or patients who had not taken any treatment for at least 4 weeks before inclusion.~Exclusion Criteria:~* History of any recent traumatic brain injury, cerebral ischemia/TIA/stroke.~* Patients with neuroendocrinal tumors.~* History of any invasive neurosurgical/non-invasive neuropsychiatric procedure.~* Patients who are already under treatment for the presenting conditions.~* Medication history of psychoactive or central nervous system depressant drugs.~* Pregnant and nursing women.~* Patients with a history of allergy to valproate, melatonin or other melatonin agonists.~* Patients with drug/alcohol abuse.~* Patients with any hepatic dysfunction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: PLACEBO_COMPARATOR): The patients in Control Arm will receive placebo with valproate (20 mg/kg).
- Melatonin Arm (Type: EXPERIMENTAL): The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).